NASDAQ:HILS Hillstream BioPharma (HILS) Stock Forecast, Price & News $0.37 +0.02 (+5.64%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$0.35▼$0.3750-Day Range$0.35▼$1.0952-Week Range$0.30▼$2.65Volume199,464 shsAverage Volume720,048 shsMarket Capitalization$4.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Hillstream BioPharma MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish7.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.27) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.25 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Hillstream BioPharma. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.40% of the float of Hillstream BioPharma has been sold short.Short Interest Ratio / Days to CoverHillstream BioPharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hillstream BioPharma has recently increased by 60.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHillstream BioPharma does not currently pay a dividend.Dividend GrowthHillstream BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HILS. Previous Next 2.6 News and Social Media Coverage News SentimentHillstream BioPharma has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Hillstream BioPharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for HILS on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows3 people have added Hillstream BioPharma to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hillstream BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders40.10% of the stock of Hillstream BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.77% of the stock of Hillstream BioPharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Hillstream BioPharma are expected to grow in the coming year, from ($0.27) to ($0.10) per share.Price to Book Value per Share RatioHillstream BioPharma has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Hillstream BioPharma (NASDAQ:HILS) StockHillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.Read More Receive HILS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HILS Stock News HeadlinesMay 15, 2023 | finance.yahoo.comHillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly AndersonMay 4, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Closing of Public Offering of Common StockMay 28, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 2, 2023 | finance.yahoo.comHillstream BioPharma Announces Closing of Public Offering of Common StockMay 2, 2023 | finance.yahoo.comHillstream BioPharma to Present at Upcoming May 2023 Investor and Industry ConferencesApril 29, 2023 | benzinga.comHillstream BioPharma Stock (NASDAQ:HILS), Short Interest ReportApril 28, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Proposed Public OfferingApril 28, 2023 | marketwatch.comHillstream BioPharma Shares Slide Premarket on Stock Offering >HILSMay 28, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.April 28, 2023 | investorplace.comWhy Is Hillstream BioPharma (HILS) Stock Down 57% Today?April 28, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Pricing of Public OfferingApril 27, 2023 | finance.yahoo.comHillstream BioPharma Announces Pricing of Public OfferingApril 27, 2023 | finance.yahoo.comHillstream BioPharma Announces Proposed Public OfferingApril 13, 2023 | tmcnet.comHillstream BioPharma Selects OncoBay Clinical to Advance ClinicalApril 13, 2023 | finance.yahoo.comHillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer MechanismApril 12, 2023 | finance.yahoo.comHillstream BioPharma’s Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To GrowApril 11, 2023 | benzinga.comHillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To GrowApril 10, 2023 | finance.yahoo.comHillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical DataMarch 28, 2023 | finance.yahoo.comHillstream BioPharma to Participate in Two Major Industry Conferences in April 2023March 23, 2023 | americanbankingnews.comDawson James Weighs in on Hillstream BioPharma, Inc.'s Q2 2023 Earnings (NASDAQ:HILS)February 28, 2023 | finance.yahoo.comHillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023February 15, 2023 | finance.yahoo.comHillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price RuleFebruary 13, 2023 | finance.yahoo.comHillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ETFebruary 13, 2023 | finance.yahoo.comHillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian CancerFebruary 10, 2023 | baystreet.caHillstream Nearly Doubles on Test ResultsFebruary 10, 2023 | msn.comHillstream Soars on Promising HSB-1216 Data in Lung CancerFebruary 10, 2023 | finance.yahoo.comIn a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis InducerSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HILS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HILS Company Calendar Today5/28/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HILS CUSIPN/A CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.03% Return on Assets-113.25% Debt Debt-to-Equity RatioN/A Current Ratio3.10 Quick Ratio5.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book1.34Miscellaneous Outstanding Shares11,510,000Free Float6,897,000Market Cap$4.31 million OptionableNot Optionable Beta3.25 Key ExecutivesMr. Randy D. Milby MBA (Age 69)Pres, Chairman & CEO Mr. Thomas P. Hess CPA (Age 59)MBA, Chief Financial Officer Key CompetitorsAmpio PharmaceuticalsNYSE:AMPEKiora PharmaceuticalsNASDAQ:KPRXFirst Wave BioPharmaNASDAQ:FWBIHistogenNASDAQ:HSTOCNS PharmaceuticalsNASDAQ:CNSPView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 38,313 shares on 5/16/2023Ownership: 0.333%Randy MilbyBought 500 shares on 6/17/2022Total: $390.00 ($0.78/share)Randy MilbyBought 1,000 shares on 6/6/2022Total: $690.00 ($0.69/share)Randy MilbyBought 1 shares on 6/1/2022Total: $0.94 ($0.94/share)View All Insider TransactionsView All Institutional Transactions HILS Stock - Frequently Asked Questions Should I buy or sell Hillstream BioPharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hillstream BioPharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HILS shares. View HILS analyst ratings or view top-rated stocks. How have HILS shares performed in 2023? Hillstream BioPharma's stock was trading at $0.3898 at the start of the year. Since then, HILS stock has decreased by 3.9% and is now trading at $0.3745. View the best growth stocks for 2023 here. Are investors shorting Hillstream BioPharma? Hillstream BioPharma saw a increase in short interest in May. As of May 15th, there was short interest totaling 263,600 shares, an increase of 60.8% from the April 30th total of 163,900 shares. Based on an average trading volume of 682,400 shares, the short-interest ratio is currently 0.4 days. Currently, 7.4% of the shares of the stock are short sold. View Hillstream BioPharma's Short Interest. When is Hillstream BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our HILS earnings forecast. When did Hillstream BioPharma IPO? (HILS) raised $21 million in an initial public offering (IPO) on Wednesday, January 12th 2022. The company issued 3,750,000 shares at $5.00-$6.00 per share. What is Hillstream BioPharma's stock symbol? Hillstream BioPharma trades on the NASDAQ under the ticker symbol "HILS." Who are Hillstream BioPharma's major shareholders? Hillstream BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.33%). View institutional ownership trends. How do I buy shares of Hillstream BioPharma? Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Hillstream BioPharma's stock price today? One share of HILS stock can currently be purchased for approximately $0.37. How much money does Hillstream BioPharma make? Hillstream BioPharma (NASDAQ:HILS) has a market capitalization of $4.31 million. How can I contact Hillstream BioPharma? The official website for the company is www.hillstreambio.com. The company can be reached via phone at 908-955-3140 or via email at investorrelations@hillstreambio.com. This page (NASDAQ:HILS) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.